M&T Bank Corp boosted its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 303.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,870 shares of the medical research company's stock after purchasing an additional 13,437 shares during the quarter. M&T Bank Corp's holdings in Bruker were worth $1,047,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of BRKR. Assetmark Inc. boosted its position in Bruker by 23.7% during the third quarter. Assetmark Inc. now owns 1,729 shares of the medical research company's stock worth $119,000 after purchasing an additional 331 shares in the last quarter. Atria Investments Inc boosted its position in Bruker by 4.4% during the third quarter. Atria Investments Inc now owns 12,698 shares of the medical research company's stock worth $877,000 after purchasing an additional 538 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its position in Bruker by 3.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 36,627 shares of the medical research company's stock worth $2,529,000 after purchasing an additional 1,267 shares in the last quarter. Aptus Capital Advisors LLC boosted its position in Bruker by 15.8% during the third quarter. Aptus Capital Advisors LLC now owns 40,522 shares of the medical research company's stock worth $2,798,000 after purchasing an additional 5,523 shares in the last quarter. Finally, KBC Group NV boosted its position in Bruker by 1.8% during the third quarter. KBC Group NV now owns 42,680 shares of the medical research company's stock worth $2,947,000 after purchasing an additional 763 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price on the stock in a research report on Thursday, December 5th. Barclays cut their price target on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Bank of America boosted their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Stifel Nicolaus cut their price target on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Finally, UBS Group started coverage on Bruker in a report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target for the company. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bruker currently has an average rating of "Moderate Buy" and a consensus target price of $70.50.
Check Out Our Latest Stock Report on Bruker
Bruker Stock Performance
Bruker stock opened at $45.56 on Wednesday. The firm has a market capitalization of $6.91 billion, a P/E ratio of 59.95, a PEG ratio of 2.16 and a beta of 1.18. The stock has a fifty day moving average price of $54.48 and a 200 day moving average price of $58.76. Bruker Co. has a 52 week low of $44.89 and a 52 week high of $94.86. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.
Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities research analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.
Bruker Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.44%. Bruker's dividend payout ratio is presently 26.32%.
Bruker Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
